As Roivant’s unicorn valuation swells to $7B, Ramaswamy scoops up $200M to back a new burst of startups
Vivek Ramaswamy never hid his ambitions in swiftly building Roivant into a global biopharma player. But now he’s offering some new details about just how successful he’s been in growing the company’s mega-blockbuster unicorn valuation while continuing to bring in significant new amounts of cash to keep adding to the number of companies and drugs under his watch.
Today Roivant is unveiling a $200 million raise for the company — bringing the total to more than $3 billion from all sources. And the biotech umbrella group — which operates a dozen public and private operations — says this new money came in with a valuation of $7 billion for Roivant — which a company spokesman says is up from $5.6 billion from its last raise in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.